Table 4.

Estimates of different values of D and tau for several EHL rFVIII concentrates by taking into account a sequence of repeated administrations. The results have been obtained by using Equation (9) with a trough level equal to 0.15 IU/ml, and with an interval tau between boluses and a value of dose, respectively, equal to 12 h and 10 IU/kg/h.

Phase I/II studies				Estimates of D with trough = 0.15 IU/ml and tau = 12 h			Estimates of tau with trough = 0.15 IU/ml and D = 10 IU/kg/h		Ref.
FVIII concentrate	Trade name	Dose (IU/kg)	Clearance (ml/h/kg)	FVIII (IU/ml)	Tau (h)	Dose (IU/kg/12 h)	Tau (h)	Dose (IU/kg/tau)
Turoctocog alfa GP	NovoEight GP	75	1.9	0.15	12	3.4	35	10	Powell and colleagues43
Turoctocog alfa	NovoEight®	50	4.17	0.15	12	7.5	16	10
Octocog alfa	Advate®	50	4.24	0.15	12	7.6	16	10
Damoctocog alfa pegol	BAY 94-9027	25	1.6	0.15	12	2.9	42	10	Collins and colleagues44
Octocog alfa-sucrose formulated	rFVIII-FS	25	2.3	0.15	12	4.1	29	10
Octocog alfa PEG	BAX 855	30	2.76	0.15	12	5.0	24	10	Stidl and colleagues16
Octocog alfa	Advate®	30	4.55	0.15	12	8.2	15	10
Ionoctocog alfa	FVIII-SingleChain	50	2.64	0.15	12	4.8	25	10	Collins and colleagues49
Octocog alfa	Advate®	50	3.68	0.15	12	6.6	18	10
Efraloctocog alfa	Eloctate®	25	1.68	0.15	12	3.0	40	10	Santagostino and colleagues45
Octocog alfa	Advate®	25	2.49	0.15	12	4.5	27	10
Efraloctocog alfa	Eloctate®	65	2.32	0.15	12	4.2	29	10
Octocog alfa	Advate®	65	3.61	0.15	12	6.5	18	10
Simoctocog	Nuwiq®	45	4.73	0.15	12	8.5	14	10	Morfini46

ABR, annualized bleeding rate; EHL, extended half-life; PK, pharmacokinetics; rF, recombinant factor.